Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy HE, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart M, Laethem JL, Flamen P.

BMC Cancer. 2013 Apr 12;13:190. doi: 10.1186/1471-2407-13-190. Erratum in: BMC Cancer. 2015;15:173.

2.

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.

Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.

PMID:
25201358
3.

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.

An MS, Yoo JH, Kim KH, Bae KB, Choi CS, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH.

World J Surg Oncol. 2015 Feb 19;13:64. doi: 10.1186/s12957-015-0488-7.

4.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators.

Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

5.

Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.

Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG.

Oncology. 2009;76(5):363-8. doi: 10.1159/000210025. Epub 2009 Mar 25.

PMID:
19321964
6.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.

Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24.

PMID:
20033812
7.

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.

Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J.

BMC Cancer. 2015 Jul 10;15:511. doi: 10.1186/s12885-015-1507-3.

8.

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2015 Dec;14(4):262-8.e1. doi: 10.1016/j.clcc.2015.05.010. Epub 2015 Jun 6.

PMID:
26123496
9.

Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.

Lu CS, Chang PY, Chen YG, Chen JH, Wu YY, Ho CL.

PLoS One. 2015 Sep 18;10(9):e0138632. doi: 10.1371/journal.pone.0138632. eCollection 2015.

10.

Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.

Oh SY, Kim DY, Kim YB, Suh KW.

World J Surg. 2013 Oct;37(10):2497-503. doi: 10.1007/s00268-013-2120-8.

PMID:
23754140
11.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
12.

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.

Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A.

Cancer. 2002 Apr 1;94(7):1931-8. Review.

13.

KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.

Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Ann Surg Oncol. 2015 Jan;22(1):187-94. doi: 10.1245/s10434-014-3826-z. Epub 2014 Jun 3.

PMID:
24889488
14.

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

Grothey A, Sargent DJ.

J Clin Oncol. 2005 May 20;23(15):3311-3. No abstract available.

PMID:
15908645
15.

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.

Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R; Arbeitsgemeinschaft Gastrointestinale Onkologie.

Ann Oncol. 2003 Mar;14(3):395-9.

PMID:
12598344
16.

Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.

Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.

17.

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.

Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY.

PLoS One. 2015 Apr 28;10(4):e0123973. doi: 10.1371/journal.pone.0123973. eCollection 2014.

18.

Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.

Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L.

Ann Surg Oncol. 2014 Aug;21(8):2636-41. doi: 10.1245/s10434-013-3438-z. Epub 2014 Mar 18.

PMID:
24639190
19.

Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.

Chang W, Wei Y, Ren L, Zhong Y, Yu Y, Chen J, Zhu D, Ye L, Qin C, Zhao N, Niu W, Qin X, Xu J.

Ann Surg. 2016 Mar;263(3):434-9. doi: 10.1097/SLA.0000000000001374.

PMID:
26465781
20.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group.

Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

PMID:
26189067

Supplemental Content

Support Center